MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
MindMed (MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced it will host a live webcast on March 6, 2025, at 8:00 a.m. ET. During the webcast, the company will present its fourth quarter and full-year 2024 financial results and provide business updates.
The webcast will be accessible through a registration link, with a separate link provided for analysts who wish to participate in the Q&A session. Participants are advised to join 15 minutes before the start time. A replay will be available through MindMed's Investor Relations website and will be archived for at least 30 days.
MindMed (MNMD), un'azienda biofarmaceutica clinica in fase avanzata focalizzata sui disturbi della salute mentale, ha annunciato che ospiterà un webcast dal vivo il 6 marzo 2025, alle 8:00 a.m. ET. Durante il webcast, l'azienda presenterà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 e fornirà aggiornamenti aziendali.
Il webcast sarà accessibile tramite un link di registrazione, con un link separato fornito per gli analisti che desiderano partecipare alla sessione di domande e risposte. Si consiglia ai partecipanti di collegarsi 15 minuti prima dell'orario di inizio. Una registrazione sarà disponibile sul sito web delle Relazioni con gli Investitori di MindMed e sarà archiviata per almeno 30 giorni.
MindMed (MNMD), una empresa biofarmacéutica clínica en etapa avanzada centrada en trastornos de la salud cerebral, ha anunciado que llevará a cabo un webcast en vivo el 6 de marzo de 2025, a las 8:00 a.m. ET. Durante el webcast, la empresa presentará sus resultados financieros del cuarto trimestre y del año completo 2024 y proporcionará actualizaciones sobre el negocio.
El webcast será accesible a través de un enlace de registro, con un enlace separado proporcionado para los analistas que deseen participar en la sesión de preguntas y respuestas. Se aconseja a los participantes unirse 15 minutos antes de la hora de inicio. Una repetición estará disponible a través del sitio web de Relaciones con Inversores de MindMed y se archivará durante al menos 30 días.
마인드메드(MNMD)는 뇌 건강 장애에 중점을 둔 후기 단계 임상 생명공학 회사로, 2025년 3월 6일 오전 8시(ET)에 라이브 웹캐스트를 개최할 것이라고 발표했습니다. 웹캐스트 동안 회사는 2024년 4분기 및 연간 재무 결과를 발표하고 비즈니스 업데이트를 제공할 것입니다.
웹캐스트는 등록 링크를 통해 접근할 수 있으며, Q&A 세션에 참여하고자 하는 분석가를 위해 별도의 링크가 제공됩니다. 참가자들은 시작 시간 15분 전에 접속할 것을 권장합니다. 재생은 마인드메드의 투자자 관계 웹사이트를 통해 제공되며 최소 30일 동안 보관됩니다.
MindMed (MNMD), une entreprise biopharmaceutique clinique en phase avancée axée sur les troubles de la santé cérébrale, a annoncé qu'elle organisera un webinaire en direct le 6 mars 2025 à 8h00 ET. Lors du webinaire, l'entreprise présentera ses résultats financiers du quatrième trimestre et de l'année 2024 et fournira des mises à jour commerciales.
Le webinaire sera accessible via un lien d'inscription, avec un lien séparé fourni pour les analystes souhaitant participer à la session de questions-réponses. Les participants sont invités à se connecter 15 minutes avant l'heure de début. Un enregistrement sera disponible sur le site des relations avec les investisseurs de MindMed et sera archivé pendant au moins 30 jours.
MindMed (MNMD), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf Störungen der Gehirngesundheit konzentriert, hat angekündigt, dass es am 6. März 2025 um 8:00 Uhr ET ein Live-Webcast veranstalten wird. Während des Webcasts wird das Unternehmen seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 präsentieren und Unternehmensupdates bereitstellen.
Der Webcast wird über einen Registrierungslink zugänglich sein, und für Analysten, die an der Q&A-Sitzung teilnehmen möchten, wird ein separater Link bereitgestellt. Die Teilnehmer werden gebeten, 15 Minuten vor Beginn der Veranstaltung beizutreten. Eine Wiederholung wird über die Investor Relations-Website von MindMed verfügbar sein und mindestens 30 Tage lang archiviert werden.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220848926/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
When will MindMed (MNMD) release its Q4 and full-year 2024 earnings?
How can investors access MindMed's Q4 2024 earnings webcast?
How long will MindMed's Q4 2024 earnings webcast replay be available?
What topics will be covered in MindMed's March 6, 2025 webcast?
